Pharmaceuticals, Biotechnology & Life Sciences

Explore how Eli Lilly’s $7 billion bid for Kelonia Therapies and its mRNA vaccine partnership with Amplitude could reshape drug innovation, diversify revenue, and challenge industry rivals.

Merck’s stock gains optimism amid mixed analyst ratings, a breakthrough mRNA cancer vaccine partnership, and rising option activity—what this means for investors.

Summit Therapeutics is advancing novel antibiotics to tackle global resistance, blending R&D, UK/US markets, and investor transparency for a resilient future.

UBS sees Bristol‑Myers Squibb as a $80 target with dividend income, but oncology’s checkpoint‑inhibitor resistance and uncertain trials keep upside under scrutiny.

Porton Pharma’s first‑half 2026 results: revenue up 10.42% to 1.79 billion CNY, net loss widened to 224 million CNY, with strong growth in APIs and cell‑gene therapy. Click to see the full story.

bioAffinity Technologies files a 1-for-15 reverse stock split to meet Nasdaq’s bid‑price rule, preserving its listing while offering cash for fractional shares.

Cypherpunk Technologies boosts its Zcash mining share to ~18 % after a $33 M Winklevoss Capital deal, raising analyst targets and positioning for privacy‑tech growth.

Johnson & Johnson’s shares soar to a 52‑week high as AI‑powered robotic bronchoscopy, EU Tecvayli approval, and strong investor sentiment signal solid growth potential.

NovaBay Pharmaceuticals focuses on niche topical anti‑infective therapies, offering rapid deployment solutions amid rising antimicrobial resistance and volatile biotech markets.

Alnylam gains Outperform ratings as BMO & Benzinga boost its RNAi‑powered ATTR pipeline, positioning the biotech stock for strong growth.